Valsartan-d8
Based on 1 Customer Validation
Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 1089736-72-0
- Formula: C24H21D8N5O3
- Molecular Weight:443.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Angiotensin Receptor Isoforms
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1089736-72-0
-
Unlabeled Cas 137862-53-4
-
Appearance Solid
-
Molecular Weight 443.57
-
Formula C24H21D8N5O3
-
Color White to off-white
-
SMILES
[2H]C([2H])([2H])C(C([2H])([2H])[2H])([2H])[C@](C(O)=O)([2H])N(C(CCCC)=O)CC1=CC=C(C=C1)C2=C(C3=NN=NN3)C=CC=C2
-
Synonyms
CGP 48933-d8
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (112.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (2.25 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Shan H, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014 Jun;18(6):1071-80. [Content Brief]
[3]. Wang Y, et al. Valsartan blocked alcohol-induced, Toll-like receptor 2 signaling-mediated inflammation in human vascular endothelial cells. Alcohol Clin Exp Res. 2014 Oct;38(10):2529-40. [Content Brief]
[4]. Sui X, et al. Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med. 2015 Aug;19(8):1773-82. [Content Brief]
[5]. Jiang Y, et al. Cardioprotective effect of valsartan in mice with short-term high-salt diet by regulating cardiac aquaporin 1 and angiogenic factor expression. Cardiovasc Pathol. 2015 Jul-Aug;24(4):224-9. [Content Brief]
[6]. Ping G, et al. Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice. Pharmacol Biochem Behav. 2014 Sep;124:5-12. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.2544 mL | 11.2722 mL | 22.5444 mL | 56.3609 mL |
| DMSO | 5 mM | 0.4509 mL | 2.2544 mL | 4.5089 mL | 11.2722 mL |
| 10 mM | 0.2254 mL | 1.1272 mL | 2.2544 mL | 5.6361 mL | |
| 15 mM | 0.1503 mL | 0.7515 mL | 1.5030 mL | 3.7574 mL | |
| 20 mM | 0.1127 mL | 0.5636 mL | 1.1272 mL | 2.8180 mL | |
| 25 mM | 0.0902 mL | 0.4509 mL | 0.9018 mL | 2.2544 mL | |
| 30 mM | 0.0751 mL | 0.3757 mL | 0.7515 mL | 1.8787 mL | |
| 40 mM | 0.0564 mL | 0.2818 mL | 0.5636 mL | 1.4090 mL | |
| 50 mM | 0.0451 mL | 0.2254 mL | 0.4509 mL | 1.1272 mL | |
| 60 mM | 0.0376 mL | 0.1879 mL | 0.3757 mL | 0.9393 mL | |
| 80 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7045 mL | |
| 100 mM | 0.0225 mL | 0.1127 mL | 0.2254 mL | 0.5636 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz